Topiramate-induced weight loss: A review

Epilepsy Research

Volumn 95, Issue 3, 2011, Pages 189-199

  Verrotti, Alberto ^a   Scaparrotta, Alessandra ^a   Agostinelli, Sergio ^a   Di Pillo, Sabrina ^a   Chiarelli, Francesco ^a   Grosso, Salvatore ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Body mass index; Children; Epilepsy; Pathogenetic mechanism; Topiramate; Weight loss

Indexed keywords

ADIPONECTIN; CARBAMAZEPINE; LEPTIN; NEUROPEPTIDE Y; PLACEBO; TOPIRAMATE; VALPROIC ACID;

ADD ON THERAPY; ANOREXIA; BODY FAT; BODY MASS; BODY WEIGHT; CALORIC INTAKE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG MECHANISM; ENERGY BALANCE; ENERGY EXPENDITURE; EPIDEMIOLOGICAL DATA; FOCAL EPILEPSY; GENDER; GLUCOSE METABOLISM; HUMAN; HYPOTHALAMUS; INSULIN SENSITIVITY; LIPID METABOLISM; LOW DRUG DOSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT DURATION; WEIGHT GAIN; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; DATABASES, FACTUAL; ENERGY METABOLISM; EPILEPSY; FRUCTOSE; HORMONES; HUMANS; OBESITY; SEX FACTORS; WEIGHT LOSS;

EID: 79960343088     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2011.05.014     Document Type: Review

References (111)

1. Albaugh V.L., Henry C.R., Bello N.T., et al. Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity (Silver Spring) 2006, 14:36-51.
2. Alberici A., Borroni B., Manelli F., et al. Topiramate weight loss in migraine patients. J. Neurol. Sci. 2009, 278:64-65.
3. Arroyo S., Dodson W.E., Privitera M.D., et al. Randomized dose-controlled study of topiramate as first-line therapy in epilepsy. Acta Neurol. Scand. 2005, 112:214-222. the EPMN-106/INT-28 Investigators.
4. Asconapè J.J. Some common issue in the use of antiepileptic drugs. Semin. Neurol. 2002, 22:27-39.
5. Astrup A., Caterson I., Zelissen P., et al. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes. Res. 2004, 12:1658-1669.
6. Baskin D.G., Schwartz M.W., Seeley R.J., et al. Leptin receptor long-form splice-variant protein expression in neuron cell bodies of the brain and co-localization with neuropeptide Y mRNA in the arcuate nucleus. J. Histochem. Cytochem. 1999, 47:353-362.
7. Ben-Menachem E., Smith U., Hellstrom K., et al. Prospective study on metabolism and weight change in patients with epilepsy treated with topiramate. Epilepsia 2000, 41:222.
8. Ben-Menachem E., Axelsen M., Johanson E.H., et al. Predictors of weight loss in adults with topiramate treated epilepsy. Obes. Res. 2003, 11:556-562.
9. Ben-Menachem E., Sander J.W., Stefan H., et al. Topiramate monotherapy in the treatment of newly or recent diagnosed epilepsy. Clin. Ther. 2008, 30:1180-1195.
10. Biton V. Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy. CNS Drugs 2003, 17:781-791.
11. Biton V., Montouris G.D., Ritter F., et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurology 1999, 52:1330-1337. the Topiramate YTC Study Group.
12. Bray G.A., York D.A. The MONA LISA hypothesis in the time of leptin. Recent Prog. Horm. Res. 1998, 53:95-117.
13. Bray G.A., Fisler J.S., York D.A. Neuroendocrine control of the development of obesity: understanding gained from studies of experimental models of obesity. Front. Neuroendocrinol. 1990, 4:128-181.
14. Bray G.A., Blackburn G.L., Ferguson J.M., et al. Sibutramine produces dose-related weight loss. Obes. Res. 1999, 7:189-198.
15. Bray G.A., Hollander P., Klein S., et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes. Res. 2003, 11:722-733.
16. Burguera B., Couce M.E., Long J., et al. The long form of the leptin receptor (OB-Rb) is widely expressed in the human brain. Neuroendocrinology 2000, 71:187-195.
17. Campfield L.A., Smith F.J., Bum P. Strategies and potential targets for obesity treatment. Science 1998, 280:1383-1387.
18. Cates M.E., Feldman J.M., Boggs A.A., et al. Efficacy of add-on topiramate therapy in psychiatric patients with weight gain. Ann. Pharmacother. 2008, 42:505-510.
19. Chengappa K.N., Chalasani L., Brar J.S., et al. Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review. Clin. Ther. 2002, 24:1576-1584.
20. Cho Y.-J., Heo K., Kim W.-J., et al. Long-term efficacy and tolerability of topiramate as add-on therapy in refractory partial epilepsy: an observational study. Epilepsia 2009, 50:1910-1919.
21. Coppola G., Caliendo G., Terracciano M.M., et al. Topiramate in refractory partial-onset seizures in children, adolescents and young adults: a multicentric open trial. Epilepsy Res. 2001, 43:255-260.
22. DeLorenzo R.J., Sombati S., Coulter D.A. Effects of topiramate on sustained repetitive firing and spontaneous recurrent seizure discharges in cultured hippocampal neurons. Epilepsia 2000, 41:S40-S44.
23. Diamond F.B., Cuthbertson D., Hanna S., Eichler D. Correlates of adiponectin and the leptin/adiponectin ratio in obese and non-obese children. J. Pediatr. Endocrinol. Metab. 2004, 17:1069-1075.
24. Dodgson S.J., Shank R.P., Maryanoff B.E. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 2000, 41:S35-39.
25. Duva M.A., Tomkins E.M., Moranda L.M., et al. Regional differences in feeding and other behaviors elicited by N-methyl-d-aspartic acid in the rodent hypothalamus: a reverse microdialysis mapping study. Brain Res. 2002, 925:141-147.
26. Edwards K.R., Glantz M.J., Button J., et al. Efficacy and safety of topiramate in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Neurology 2000, 54:A81.
27. Elmquist J.K., Ahima R.S., Elias C.F., et al. Leptin activates distinct projections from the dorsomedial and ventromedial hypothalamic nuclei. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:741-746.
28. Elmquist J.K., Maratos-Flier E., Saper C.B., Flier J.S. Unraveling the central nervous system pathways underlying the responses to leptin. Nat. Neurosci. 1998, 1:445-450.
29. Erfurth A., Kuhn G. Topiramate monotherapy in the maintenance treatment of bipolar I disorder: effects on mood, weight and serum lipids. Neuropsychobiology 2000, 42:S50-51.
30. Eschle R.F. Data on File 1997, Ortho-McNeil Pharmaceuticals Clinical Affairs.
31. Faught E. Topiramate in the treatment of partial and generalized epilepsy. Neuropsychiatr. Dis. Treat. 2007, 3:811-821.
32. Gabriel A. Adjunctive topiramate treatment in refractory obese bipolar patients: a descriptive open label study. Eat. Weight Disord. 2007, 12:48-53.
33. Gilliam F.G., Veloso F., Bomhof M.A.M., et al. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology 2003, 60:196-202.
34. Giovambattista A., Chisari A.N., Gaillard R.C., Spinedi E. Food intake-induced leptin secretion modulates hypothalamo-pituitary-adrenal axis response and hypothalamic Ob-Rb expression to insulin administration. Neuroendocrinology 2000, 72:341-349.
35. Gold M.S., Star J. Eating disorders. Substance Abuse: A Comprehensive Textbook 2004, 469-488. Williams and Wilkins, York, PN. 2nd ed. H.L. Joyce, R. Pedro, B.M. Robert (Eds.).
36. Groselj J., Guerrini R., Van Oene J., et al. Experience with topiramate monotherapy in elderly patients with recent-onset epilepsy. Acta Neurol. Scand. 2005, 112:144-150. the TOP-INT-51 Investigators' Group.
37. Gryder D.S., Rogawski M.A. Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J. Neurosci. 2003, 23:7069-7074.
38. Guerrini R., Carpay J., Groselj J., et al. Topiramate monotherapy as broad-spectrum antiepileptic drug in a naturalistic clinical setting. Seizure 2005, 14:371-380.
39. Harden C.L. New antiepileptic drugs. Neurology 1994, 44:787-795.
40. Heinrichs S.C., Menzaghi F., Pich E.M., et al. Corticotrophin-releasing factor in paraventricular nucleus modulates feeding induced by neuropeptide Y. Brain Res. 1993, 611:18-24.
41. Herrero A.I., Del Olmo N., Gonzàlez-Escalada J.R., Solìs J.M. Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance. Neuropharmacology 2002, 42:210-220.
42. Husum H., Van Kammen D., Termeer E., et al. Topiramate normalizes hippocampal NPY-LI in flinders sensitive line 'depressed' rats and up-regulates NPY, galanin, and CRH-LI in the hypothalamus: implications for mood-stabilizing and weight loss-inducing effects. Neuropsychopharmacology 2003, 28:1292-1299.
43. Kaminski R.M., Banerjee M., Rogawski M.A. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology 2004, 46:1097-1104.
44. Klein K.M., Theisen F., Knake S., et al. Topiramate, nutrition and weight change: a prospective study. J. Neurol. Neurosurg. Psychiatry 2008, 79:590-593.
45. Krahn D.D., Gosnell B.A., Grace M., Levine A.S. CRF antagonist partially reverses CRF- and stress-induced effects on feeding. Brain Res. Bull. 1986, 17:285-289.
46. Kyrkouli S.E., Stanley B.G., Seirafi R.D., Leibowitz S.F. Stimulation of feeding by galanin: anatomical localization and behavioral specificity of this peptide's effects in the brain. Peptides 1990, 11:995-1001.
47. Lalonde J., Samson P., Poulin S., et al. Additive effects of leptin and topiramate in reducing fat deposition in lean and obese ob/ob mice. Physiol. Behav. 2004, 80:415-420.
48. Landmark C.J. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 2008, 22:27-47.
49. Levisohn P.M. Safety and tolerability of topiramate in children. J. Child Neurol. 2000, 15:S22-26.
50. Li H.F., Zou Y., Xia Z.Z., et al. Effects of topiramate on weight and metabolism in children with epilepsy. Acta Paedìatr. 2009, 98:1521-1525.
51. Liang Y., She P., Wang X., Demarest K. The messenger RNA profiles in liver, hypothalamus, white adipose tissue, and skeletal muscle of female Zucker diabetic fatty rats after topiramate treatment. Metabolism 2006, 55:1411-1419.
52. Maryanoff B.E. Sugar sulfamates for seizure control: discovery and development of topiramate, a structurally unique antiepileptic drug. Curr. Top. Med. Chem. 2009, 9:1049-1062.
53. Maryanoff B.E., Nortey S.O., Gardocki J.F., et al. Anticonvulsant O-alkyl sulfamates 2,3:4,5-Bis-O-(l-methylethylidene)-beta-d-fructopyranose sulfamate and related compounds. J. Med. Chem. 1987, 30:880-887.
54. McElroy S.L., Suppes T., Keck P.E., et al. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol. Psychiatry 2000, 47:1025-1033.
55. McElroy S.L., Frye M.A., Altshuler L.L., et al. A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. Bipolar Disord. 2007, 9:426-434.
56. McElroy S.L., Hudson J.I., Capece J.A., et al. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol. Psychiatry 2007, 61:1039-1048. Topiramate Binge Eating Disorder Research Group.
57. Mizuno T.M., Mobbs C.V. Hypothalamic agouti-related protein messenger ribonucleic acid is inhibited by leptin and stimulated by fasting. Endocrinology 1999, 140:814-817.
58. Mohamed K., Appleton R., Rosenbloom L. Efficacy and tolerability of topiramate in childhood and adolescent epilepsy: a clinical experience. Seizure 2000, 9:137-141.
59. Montouris G.D., Biton V., Rosenfeld W.E. Non focal generalized tonic-clonic seizures: response during long-term topiramate treatment. Epilepsia 2000, 41:S77-81. the Topiramate YTC/YTCE Study Group.
60. Narula P.K., Rehan H.S., Unni K.E., Gupta N. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophr. Res. 2010, 118:218-223.
61. Nowak K.W., Pierzchala-Koziec K., Tortorella C., et al. Effects of prolonged leptin infusion on rat pituitary adrenocortical function. Int. J. Mol. Med. 2002, 9:61-64.
62. O'Connor H.T., Richman R.M., Steinbeck K.S., Caterson I.D. Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up. Int. J. Obes. Relat. Metab. Disord. 1995, 19:181-189.
63. Ogawa Y., Kikuchi T., Nagasaki K., et al. Usefulness of serum adiponectin level as a diagnostic marker of metabolic syndrome in obese Japanese children. Hypertens. Res. 2005, 28:51-57.
64. Oldani A., Manconi M., Zucconi M., et al. Topiramate treatment for nocturnal frontal lobe epilepsy. Seizure 2006, 15:649-652.
65. Ormorod R., McClellan K. Topiramate: a review of its use in childhood epilepsy. Paediatr. Drugs 2001, 3:293-319.
66. Pelleymounter M.A., Cullen M.J., Baker M.B., et al. Effect of the obese gene product on body weight regulation in ob/ob mice. Science 1995, 269:540-543.
67. Pellock J.M., Morton L.D. Treatment of epilepsy in the multiply handicapped. Ment. Retard. Dev. Disabil. Res. Rev. 2000, 6:309-323.
68. Perucca E. Clinical pharmacology and therapeutic use of the new antiepileptic drugs. Fundam. Clin. Pharmacol. 2001, 15:405-417.
69. Picard F., Deshaies Y., Lalonde J., et al. Topiramate reduces energy and fat gains in lean (Fa/?.) and obese (fa/fa) Zucker rats. Obes. Res. 2000, 8:656-663.
70. Privitera M.D., Brodie M.J., Mattson R.H., et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol. Scand. 2003, 107:165-175.
71. Ramos E.J.B., Meguid M.M., Campos A.C.L., Coelho J.C.U. Neuropeptide Y, α-melanocyte-stimulating hormone, and monoamines in food intake regulation. Nutrition 2005, 21:269-279.
72. Reife R., Pledger G., Wu S.C. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia 2000, 41:S66-S71.
73. Reiter E., Feucht M., Hauser E., et al. Changes in body mass index during long-term topiramate therapy in paediatric epilepsy patients - a retrospective analysis. Seizure 2004, 13:491-493.
74. Richard D., Ferland J., Lalonde J., et al. Influence of topiramate in the regulation of energy balance. Nutrition 2000, 16:961-966.
75. Richard D., Picard F., Lemieux C., et al. The effects of topiramate and sex hormones on energy balance of male and female rats. Int. J. Obes. 2002, 26:344-353.
76. Riviello J.J., Wheless J., Wu S.C., Schwabe S. Body weight changes during topiramate therapy in children with epilepsy. Epilepsia 1999, 40:127.
77. Rosenfeld W.E. Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clin. Ther. 1997, 19:1294-1308.
78. Rosenfeld W.E., Holmes G.B., Hunt T.L., Schaefer P. Topiramate - effective dosing enhances potential for success. Epilepsia 1992, 3:118.
79. Sachdeo R.C., Glauser T.A., Ritter F., et al. A double-blind, randomized trial of topiramate in Lennox - Gastaut syndrome. Neurology 1999, 52:1882-1887. Topiramate YL Study Group.
80. Schneiderhan M.E., Marvin R. Is acetazolamide similar to topiramate for reversal of antipsychotic-induced weight gain?. Am. J. Ther. 2007, 14:581-584.
81. Schreiner A., Stollhoff K., Ossig W., et al. Conversion from valproic acid onto topiramate in adolescents and adults with epilepsy. Acta Neurol. Scand. 2009, 119:304-312. on behalf of the TOPMAT-EPY-403 investigators.
82. Schwartz M., Seeley R.J., Campfield L.A., et al. Identification of targets of leptin action in rat hypothalamus. J. Clin. Invest. 1996, 98:1101-1106.
83. Schwartz M.W., Seeley R.J., Woods S.C., et al. Leptin increases hypothalamic pro-opiomelanocortin mRNA expression in the rostral arcuate nucleus. Diabetes 1997, 46:2119-2123.
84. Shapira N.A., Goldsmith T.D., McElroy S.L. Treatment of binge-eating disorder with topiramate: a clinical case series. J. Clin. Psychiatry 2000, 61:368-372.
85. Shuaib A., Ahmad F., Kochanski P., et al. Efficacy of topiramate in prophylaxis of frequent severe migraines or chronic daily headaches: experience with 70 patients over 18 months. Cephalalgia 2000, 20:423.
86. Smith U., Axelsen M., Hellebö-Johanson E., et al. Topiramate, a novel epileptic drug, reduces body weight and food intake in obesity. Obes. Res. 2000, 8:10S.
87. Song J.H., Tan L., Zhu Q.X. Influence of topiramate on insulin and leptin S levels in epileptic patients. Chin. J. New Drugs Clin. Remedies 2006, 25:14-16.
88. Stanley B.G., Ha L.H., Spears L.C., Dee M.G. Lateral hypothalamic injections of glutamate, kainic acid, d,l-alpha-amino-3-hydroxy-5-methyl-isoxazole propionic acid or N-methyl-d-aspartic acid rapidly elicit intense transient eating in rats. Brain Res. 1993, 613:88-95.
89. Stephen L.J., Sills G.J., Brodie M.J. Topiramate in refractory epilepsy: a prospective observational study. Epilepsia 2000, 41:977-980.
90. Supuran C.T., Di Fiore A., De Simone G. Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin. Emerg. Drugs 2008, 13:383-392.
91. Teter C.J., Early J.J., Gibbs C.M. Treatment of affective disorder and obesity with topiramate. Ann. Pharmacother. 2000, 34:1262-1265.
92. Tilg H., Moschen A.R. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat. Rev. Immunol. 2006, 6:772-783.
93. Tremblay A., Chaput J.P., Bérubé-Parent S., et al. The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension. Eur. J. Clin. Pharmacol. 2007, 63:123-134.
94. Van Ameringen M., Mancini C., Pipe B., et al. Topiramate treatment for SSRI-induced weight gain in anxiety disorders. J. Clin. Psychiatry 2002, 63:981-984.
95. Van Gaal L.F., Broom J.I., Enzi G., Toplak H. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Eur. J. Clin. Pharmacol. 1998, 54:125-132. Orlistat Dose-Ranging Study Group.
96. Verrotti A., Greco R., Giannuzzi R., et al. Old and new antiepileptic drugs for the treatment of idiopathic generalized epilepsies. Curr. Clin. Pharmacol. 2007, 2:49-59.
97. Verrotti A., Sofìa V., Franzoni E., et al. Topiramate in frontal lobe epilepsy. Acta Neurol. Scand. 2007, 115:132-135.
98. Von Seggern R.L., Mannix L.K., Adelman J.U. Efficacy of topiramate in prophylactic treatment of migraines in patients refractory to preventative intervention: a retrospective chart review in a tertiary clinic. Cephalalgia 2000, 20:423.
99. White H.S. Molecular pharmacology of topiramate: managing seizures and preventing migraine. Headache 2005, 45:S48-S56.
100. White H.S., Brown S.D., Woodhead J.H., et al. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res. 1997, 28:167-179.
101. White H.S., Brown S.D., Woodhead J.H., et al. Topiramate modulates GABA-evoked currents in murine cortical neurons by a non benzodiazepine mechanism. Epilepsia 2000, 41:S17-20.
102. Wilkes J.J., Nelson E., Osborne M., et al. Topiramate is an insulin-sensitizing compound in vivo with direct effects on adipocytes in female ZDF rats. Am. J. Physiol. Endocrinol. Metab. 2005, 288:E617-E624.
103. Wilkes J.J., Nguyen M.T., Bandyopadhyay G.K., et al. Topiramate treatment causes skeletal muscle insulin sensitization and increased Acrp30 secretion in high-fat-fed male Wistar rats. Am. J. Physiol. Endocrinol. Metab. 2005, 289:E1015-E1022.
104. Wilson M.C. Efficacy of topiramate in the prophylactic treatment of intractable chronic migraine: retrospective chart review. Cephalalgia 2000, 20:301.
105. Woods S.C., Seeley R.J., Porte D., Schwartz M.W. Signals that regulate food intake and energy homeostasis. Science 1998, 280:1378-1383.
106. Yamauchi T., Kamon J., Minokoshi Y., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 2002, 8:1288-1295.
107. York D.A. Peripheral and central mechanisms regulating food intake and macro-nutrient selection. Obes. Surg. 1999, 9:471-479.
108. York D.A., Singer L., Thomas S., Bray G.A. Effect of topiramate on body weight and body composition of Osborne-Mendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs. Nutrition 2000, 16:967-975.
109. Zeni L.A., Seidler H.B., De Carvalho N.A., et al. Glutamatergic control of food intake in pigeons: effects of central injections of glutamate, NMDA, and AMPA receptor agonists and antagonists. Pharmacol. Biochem. Behav. 2000, 65:67-74.
110. Zhang X., Velumian A.A., Jones O.T., Carlen P.L. Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia 2000, 41:S52-60.
111. Zheng H., Patterson C., Berthoud H.R. Behavioral analysis of anorexia produced by hindbrain injections of AMPA receptor antagonist NBQX in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2002, 282:R147-R155.